file copy

5 F	FOREI OI LUDIN	GN F	UMBE	R 8 NT DO	8 CUME	O	CEPTOR POLY T DATE Jan. 21, 1997	NAME Weinshank et a	RE	CEIVED	SUB
F DOCU	FOREI UMEN 01 LUDIN	GN F	PATEN UMBER	8 NT DO					RE		CLA
DOCU WO RT (INC	ONE I	GN F	PATEN	NT DO			Jan. 21, 1997		RE		CLA
WO WO RT (INC	UMEN 01 LUDIN DNEN P	T NU	MBE	₹	CUME	ENTS		onstance a	RE	CEIVED	+-
WO WO RT (INC	UMEN 01 LUDIN DNEN P	T NU	MBE	₹	CUME	ENTS			RE	CEIVED)
WO WO RT (INC	UMEN 01 LUDIN DNEN P	T NU	MBE	₹	CUME	ENTS				. —	7
WO WO RT (INC	UMEN 01 LUDIN DNEN P	T NU	MBE	₹	CUME	NTS		i	, Ja	AN 1 0 2003	+
RT (INC	01 LUDIN	2							 J/		1
RT (INC	LUDIN		9	0			DATE	COUNTRY T	ECH/	CENTER 1600	ZGJU SUB
LUCINO	MEN P				8	2	April 26, 2001	PCT		CLASS	CLA
LUCINO	MEN P										==
LUCINO	MEN P										ļ
JEWEL for agor Septemb	L-MOT nist-proper 1995	Z, E.A moted 5, page	A. et al: phosples 1194	"An achorylatio	cidic moon and o	tif within	n the third intracellu zation." Biochemis	lar loop of the alpha try, United States 1	2C2 adr 19 Sep.	renergic receptor is 1995, Vol. 34, N	requir o. 37,
MAKAR Hyperten MICHEL Dialysis, Associati	ITSIS Sision. U M.C., Transpon. Eng	K.P., Jnited et al: planta gland,	et al: States, "Function: Nov. 1	"Role Jan. 199 ional co Official 999, Vo	of the 99, Vol. rrelates Public	alpha2B 33, No. of alpha ation of	-adrenergic recepto 1, January 1999, pag (2A)-adrenoceptor g the European Di ges 2657-2663.	r in the developme ges 14-17. ene polymorphism i alysis and Transpl	ent of s	alt-induced hyperal ANE study." Nep	tension hrology n Rena
oj ine Am	erican I	Society	v of Hyp	pertensi	on. Uni	ted State	s, Sep. 1995, Vol. 8	No. 9, pages 863-8	ournai 69.	of Hypertension:	Journa
SMALL I G protein United Sta	K.M., et -couple ates, 16	t al: " ed rece Feb 2	Polymo eptor k 001, Vo	orphic de inase-m ol. 276,	eletion of ediated No. 7, pa	of three in phosphorages 491	ntracellular acidic re orylation and desen 7-4922.	esidues of the alpha sitization." The J	2B-adre	of Biological Che	emistry
SNAPIR A for acute of 1516-1522	A., et al coronar	l: "An y even	inserti its." <i>Jo</i>	on/deletournal o	tion poly f the An	morphis	sm in the alpha2B-a College of Cardiolo	drenergic receptor g	gene is a May 200	novel genetic risk 01, Vol. 37, No. 6	factor
I a a	JEWEL for agor September 19 Sep	JEWELL-MOT for agonist-pro September 1995. COMINGS, D. hyperactivity di 55, No. 3, pages MAKARITSIS Hypertension. UMICHEL M.C., Dialysis, Transp. Association. En FREEMAN K., aggregation, barrof the American of the American Semantic States, 16 SNAPIR A., et allor acute coronar, 516-1522.	JEWELL-MOTZ, E.A for agonist-promoted September 1995, page COMINGS, D.E., et hyperactivity disorder 55, No. 3, pages 160-155, No. 3, pages 160-155, No. 3, pages 160-156,	JEWELL-MOTZ, E.A. et al: for agonist-promoted phospi September 1995, pages 1194 COMINGS, D.E., et al: hyperactivity disorder and les 55, No. 3, pages 160-172. MAKARITSIS K.P., et al: Hypertension. United States, MICHEL M.C., et al: "Funct Dialysis, Transplantation: Association. England, Nov. 1 FREEMAN K., et al: "Get aggregation, baroreceptor sense of the American Society of Hypersension of the American Society of Hypersension of the Sample of	JEWELL-MOTZ, E.A. et al: "An act for agonist-promoted phosphorylatic September 1995, pages 11946-11953." COMINGS, D.E., et al: "Additive hyperactivity disorder and learning of 55, No. 3, pages 160-172. MAKARITSIS K.P., et al: "Role Hypertension. United States, Jan. 199." MICHEL M.C., et al: "Functional condition." Official Association. England, Nov. 1999, Vo. 1	JEWELL-MOTZ, E.A. et al: "An acidic mo for agonist-promoted phosphorylation and of September 1995, pages 11946-11953. COMINGS, D.E., et al: "Additive effect hyperactivity disorder and learning disabilities 55, No. 3, pages 160-172. MAKARITSIS K.P., et al: "Role of the Hypertension. United States, Jan. 1999, Vol. MICHEL M.C., et al: "Functional correlates Dialysis, Transplantation: Official Public Association. England, Nov. 1999, Vol. 14, No. FREEMAN K., et al: "Genetic polymorphaggregation, baroreceptor sensitivity, and salt of the American Society of Hypertension. United States, 16 Feb 2001, Vol. 276, No. 7, p. SNAPIR A., et al: "An insertion/deletion polyfor acute coronary events." Journal of the Am 516-1522.	JEWELL-MOTZ, E.A. et al: "An acidic motif within for agonist-promoted phosphorylation and desensiti September 1995, pages 11946-11953. COMINGS, D.E., et al: "Additive effect of three hyperactivity disorder and learning disabilities in Tou 55, No. 3, pages 160-172. MAKARITSIS K.P., et al: "Role of the alpha2B Hypertension. United States, Jan. 1999, Vol. 33, No. MICHEL M.C., et al: "Functional correlates of alpha Dialysis, Transplantation: Official Publication of Association. England, Nov. 1999, Vol. 14, No. 11, pages 485. "FREEMAN K., et al: "Genetic polymorphism of aggregation, baroreceptor sensitivity, and salt excretion of the American Society of Hypertension. United States SMALL K.M., et al: "Polymorphic deletion of three is 5 protein-coupled receptor kinase-mediated phospholymided States, 16 Feb 2001, Vol. 276, No. 7, pages 491. "SNAPIR A., et al: "An insertion/deletion polymorphism or acute coronary events." Journal of the American 6516-1522.	JEWELL-MOTZ, E.A. et al: "An acidic motif within the third intracellul for agonist-promoted phosphorylation and desensitization." Biochemis September 1995, pages 11946-11953. COMINGS, D.E., et al: "Additive effect of three noradrenergic ger hyperactivity disorder and learning disabilities in Tourette syndrome sub 55, No. 3, pages 160-172. MAKARITSIS K.P., et al: "Role of the alpha2B-adrenergic receptor Hypertension. United States, Jan. 1999, Vol. 33, No. 1, January 1999, page MICHEL M.C., et al: "Functional correlates of alpha(2A)-adrenoceptor general Dialysis, Transplantation: Official Publication of the European Dialysis, Transplantation: Official Publication of the European Dialysis, Transplantation: Official Publication of the alpha 2-adreneral Association. England, Nov. 1999, Vol. 14, No. 11, pages 2657-2663. FREEMAN K., et al: "Genetic polymorphism of the alpha 2-adreneral aggregation, baroreceptor sensitivity, and salt excretion in normotensive has aggregation, baroreceptor sensitivity, and salt excretion in normotensive has aggregation, baroreceptor kinase-mediated phosphorylation and desensible of the American Society of Hypertension. United States, Sep. 1995, Vol. 8, SMALL K.M., et al: "Polymorphic deletion of three intracellular acidic responsion-coupled receptor kinase-mediated phosphorylation and desensible States, 16 Feb 2001, Vol. 276, No. 7, pages 4917-4922. SNAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-actor acute coronary events." Journal of the American College of Cardiology 516-1522.	JEWELL-MOTZ, E.A. et al: "An acidic motif within the third intracellular loop of the alpha for agonist-promoted phosphorylation and desensitization." <i>Biochemistry</i> , United States 1 September 1995, pages 11946-11953. COMINGS, D.E., et al: "Additive effect of three noradrenergic genes (ADRA2a, AD hyperactivity disorder and learning disabilities in Tourette syndrome subjects." <i>Clinical Genesis</i> , No. 3, pages 160-172. MAKARITSIS K.P., et al: "Role of the alpha2B-adrenergic receptor in the development Hypertension. United States, Jan. 1999, Vol. 33, No. 1, January 1999, pages 14-17. MICHEL M.C., et al: "Functional correlates of alpha(2A)-adrenoceptor gene polymorphism. <i>Association. England</i> , Nov. 1999, Vol. 14, No. 11, pages 2657-2663. FREEMAN K., et al: "Genetic polymorphism of the alpha 2-adrenergic receptor is alaggregation, baroreceptor sensitivity, and salt excretion in normotensive humans." <i>American of the American Society of Hypertension</i> . United States, Sep. 1995, Vol. 8, No. 9, pages 863-8 SMALL K.M., et al: "Polymorphic deletion of three intracellular acidic residues of the alpha 3 Grotein-coupled receptor kinase-mediated phosphorylation and desensitization." <i>The Journal of the American College of Cardiology</i> . United States, 16 Feb 2001, Vol. 276, No. 7, pages 4917-4922. SNAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-adrenergic receptor go acute coronary events." <i>Journal of the American College of Cardiology</i> . United States, 15 DATE CONSIDERED	JEWELL-MOTZ, E.A. et al: "An acidic motif within the third intracellular loop of the alpha2C2 adr for agonist-promoted phosphorylation and desensitization." <i>Biochemistry</i> , United States 19 Sep. September 1995, pages 11946-11953. COMINGS, D.E., et al: "Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, hyperactivity disorder and learning disabilities in Tourette syndrome subjects." <i>Clinical Genetics</i> , E 55, No. 3, pages 160-172. MAKARITSIS K.P., et al: "Role of the alpha2B-adrenergic receptor in the development of s <i>Hypertension</i> . United States, Jan. 1999, Vol. 33, No. 1, January 1999, pages 14-17. MICHEL M.C., et al: "Functional correlates of alpha(2A)-adrenoceptor gene polymorphism in the H Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association. England, Nov. 1999, Vol. 14, No. 11, pages 2657-2663. FREEMAN K., et al: "Genetic polymorphism of the alpha 2-adrenergic receptor is associate aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans." <i>American Journal of the American Society of Hypertension</i> . United States, Sep. 1995, Vol. 8, No. 9, pages 863-869. SMALL K.M., et al: "Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic protein-coupled receptor kinase-mediated phosphorylation and desensitization." <i>The Journal Journal of the American College of Cardiology</i> . United States, May 200 (SNAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a protein-coupled receptor." <i>Journal of the American College of Cardiology</i> . United States, May 200 (SIAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a protein-coupled receptor." <i>Journal of the American College of Cardiology</i> . United States, May 200 (SIAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a protein-couple of the American College of Cardiology. United States, May 200 (SIAPIR A., et al: "An insertion/delet	JEWELL-MOTZ, E.A. et al: "An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is for agonist-promoted phosphorylation and desensitization." <i>Biochemistry</i> , United States 19 Sep. 1995, Vol. 34, No. September 1995, pages 11946-11953. COMINGS, D.E., et al: "Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention hyperactivity disorder and learning disabilities in Tourette syndrome subjects." <i>Clinical Genetics</i> , Denmark, March 1955, No. 3, pages 160-172. MAKARITSIS K.P., et al: "Role of the alpha2B-adrenergic receptor in the development of salt-induced hyperthypertension. United States, Jan. 1999, Vol. 33, No. 1, January 1999, pages 14-17. MICHEL M.C., et al: "Functional correlates of alpha(2A)-adrenoceptor gene polymorphism in the HANE study." <i>Nep. Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association-European Association</i> . England, Nov. 1999, Vol. 14, No. 11, pages 2657-2663. FREEMAN K., et al: "Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans." <i>American Journal of Hypertension:</i> 1995, Vol. 8, No. 9, pages 863-869. SMALL K.M., et al: "Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor de Juited States, 16 Feb 2001, Vol. 276, No. 7, pages 4917-4922. SMAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk or acute coronary events." <i>Journal of the American College of Cardiology.</i> United States, May 2001, Vol. 37, No. 6, 100-100-1000.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.

857464v1 10738-44

Diana B

OIPE	FEEMATION DISCLOSUR	F CITATION	Copy ATTY DOCKET NO. 13092		SERIAL NO. 09/	636,259
	Use several sheets if nece	essary)	FILING		GROUP	
			August 10,			1645
XAMINER X	MARKU		J.S. PATENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·		
ITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
(S)	5,648,482	07/15/97	Meyer		RECE	VED
	5,846,710	12/08/98	Bajaj		APR 1	0 2001
	5,856,092	01/05/99	Dale et al.			R 1600/2900
	5,888,819	03/30/99	Goelet et al.		I LON OLIVII	11 1000/2300
	5,981,174	11/09/99	Wolf et al.	~		
	6,004,744	12/21/99	Goelet et al.			
	6,013,431	01/11/00	Soderlund et al.			
DD	6,156,503	12/05/00	Drazen et al.			
		FOR	REIGN PATENT DOCUMENTS	<u> </u>		L
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	1					
	OTHER DOCUM	ENTS (Includi	ing Author, Title, Date, Pertine	nt Pages, Etc.))	
129	Limbird, L.E. (1988)	FASEB J 2, 2686	-2695.			
D	Luttrell, L.M., van Bie Bridging Basic Science Press.	sen, T., Hawes, B with Clinical Mo	8.E., Della Rocca, G.J., Luttrell, D. edicine (Goldstein, D.S., Eisenhofe	K., and Lefkowit r, G., and McCar	tz, R.J. (1998) i rty, R., eds) pp.	n Catecholamines: 466-470, Academic
MINER -	Diana B		DATE CONSIDERED	3/5/03		
MINER: In	itial if reference considered, wheth	ner or not citation is emmunication to a	s in conformance with MPEP 609; Dr	aw line through cit	tation if not in co	nformance and not

Form PTO-A820 (also form PTO-1449)

P09C/REV03

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

OIPE		Docket Number (Optional) 13092	Application Number 09/636,259			
	TION DISCLOSURE CITATION (Vise several sheets if necessary)	Applicant(s) Small et al.				
APR 0 9 2001	3	Filing Date August 10, 2000	Group Art Unit			
ENDINER INITIAL PAOEMAR	OTHER DOCUMENTS (Including Author, Tit.		1045			
INITIAL HADE	Ruffolo, R.R., Jr., Nichols, A.J., Stadel, J.M., and F		col Toxicol 32, 243-279.			
DOD)			RECEIVED			
	Hein, L., Altman, J.D., and Kobilka, B.K. (1999) N	ature 402, 181-184.	APR 1 0 2001			
		TI	ECH CENTER 1600/2900			
	Altman, J.D., Trendelenburg, A.U., MacMillan, L., Mol.Pharmacol. 56, 154-161.	Bernstein, D., Limbird, L., Starke, K.	, Kobilka, B.K., and Hein, L. (1999)			
·	Lakhlani, P.P., MacMillan, L.B., Guo, T.Z., McCoo Acad Sci USA 94, 9950-9955.	ol, B.A., Lovinger, D.M., Maze, M., an	d Limbird, L.E. (1997) Proc Natl			
	Holmes, B., Brogden, R.N., Heel, R.C., Speight, T.N	, .				
	Dao, T.T., Kailasam, M.T., Parmer, R.J., Le, H.V., O'Connor, D.T. (1998) J Hypertens 16, 779-792.	Le Verge, R., Kennedy, B.P., Ziegler,	G., Insel, P.A., Wright, F.A., and			
	Goldstein, D.S., Grossman, E., Listwak, S., and Foli					
	Lockette, W., Ghosh, S., Farrow, S., MacKenzie, S., 8, 390-394.	Baker, S., Miles, P., Schork, A., and C	Cadaret, L. (1995) Am J Hypertens			
	Svetkey, L.P., Timmons, P.Z., Emovon, O., Anderso	n, N.B., Preis, L., and Chen, YT. (19	96) Hypertension 27, 1210-1215.			
	Liggett, S.B. (1998) Clin and Exp.Allergy 28, 77-79					
Open	Guyer, C.A., Horstman, D.A., Wilson, A.L., Clark, 17307-17317. Onions, K.L., Hunt, S.C., Rutkowski, M.P., Klanke, C.A., Su, Y.R., Reif, M., a		·			
PS)	Rutkowski, M.P., Klanke, C.A., Su, Y.R., Reif, M., a	and Menon, A.G. (1998) Hypertension	1 31, 1230-1234.			
Dava Dishard Date considered 3503						
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and						

P098/REV04

not considered. Include copy of this form with next communication to applicant.

	-		Docket Number (Optional) 13092	Application Number 09/636,259
011	'INFORM	MATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) Small et al.	<u> </u>
APR 0	9 2001 E)	Filing Date August 10, 2000	Group Art Unit
*EXAMINI INITIAL TRAD	NER E	OTHER DOCUMENTS (Including Author, Tite	itle, Date, Pertinent Pages, Etc.)	10.0
INITIAL TRAD	DEMA	Eason, M.G. and Liggett, S.B. (1992) J.Biol.Chem.	n. 267. 25473-25479.	
1300	1		,	RECEIVED
-	-	Jewell-Motz, E.A. and Liggett, S.B. (1996) J.Biol.C	Chem. 271, 18082-18087.	APR 1 0 2001
			TF	ECH CENTER 1600/2900
		de chasseval, R. and de Villartay, JP. (1991) Nucl	leic Acids Research 20, 245-250.	-
,		Eason, M.G., Moreira, S.P., and Liggett, S.B. (1995	5) J.Biol.Chem. 270, 4681-4688.	
		Jewell-Motz, E.A., Donnelly, E.T., Eason, M.G., and	d Liggett, S.B. (1998) Biochem 37, 15	5720-15725.
		Schwinn, D.A., Page, S.O., Middleton, J.P., Lorenz, Cotecchia, S. (1991) Mol.Pharmacol. 40, 619-626.	, W., Liggett, S.B., Yamamoto, K., Car	ron, M.G., Lefkowitz, R.J., and
		Martin, T.F.J. (1983) J Biol Chem 258, 14816-1482	<i>t</i> 2.	
		Eason, M.G., Jacinto, M.T., Theiss, C.T., and Ligger	ett, S.B. (1994) Proc.Natl.Acad.Sci., U	SA 91, 11178-11182.
		Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, Olson, B.J., and Klenk, D.C. (1985) Anal.Biochem.	A.K., Gartner, F.H., Provenzano, M.I 150, 76-85.	D., Fujimoto, E.K., Goeke, N.M.,
		Eason, M.G. and Liggett, S.B. (1996) J.Biol.Chem. 2	271, 12826-12832.	
		Exton, J.H. (1996) Annu Rev Pharmacol Toxicol 36		
W	9	MacMillan, L.B., Lakhlani, P., Lovinger, D., and Lin	mbird, L.E. (1998) Recent Prog Horm	1 Res 53, 25-42.
EXAMINER	Dic	Cina B	DATE CONSIDERED 3/5/0	23
EXAMINE	R: Initial if	f citation considered, whether or not citation is in conforman	ace with MPEP Section 609; Draw line thr	ough citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

De Stone of Bullet . Lat.	V Marie Line	to the want of the second the second to the		. 8., 88. 4.
	· 		Docket Number (Optional)	Application Number 09/636.259
\0\P\	DAN	ATION DISCLOSURE CITATION	Applicant(s)	09/030.239
	Š	Use several sheets if necessary)	Small et al.	
APR 0 9	2001	<u>.</u>)	Filing Date	Group Art Unit
\0 F1"	- *	2 '	August 10, 2000	1645
AMINER TO THE PARTY AND THE PA	MARK	OTHER DOCUMENTS (Including Author, Ti	•	
Three]	Makaritsis, K.P., Johns, C., Gavras, I., Altman, J. 405-407.	D., Handy, D.E., Bresnahan, M.R., a	
(טינו				RECEIVED
		Spiegel, A.M. (1996) Annu Rev Physiol 58, 143-17	70.	APR 1 0 2001
			TE	ECH CENTER 1600/2900
	 			
.		Kotanko, P., Binder, A., Tasker, J., DeFreitas, P., 30, 773-776.	Kamdar, S., Clark, A.J., Skrabal, F.,	and Caulfield, M. (1997) Hypertension
	•			
		Liggett, S.B., Wagoner, L.E., Craft, L.L., Hornung 102, 1534-1539.	g, R.W., Hoit, B.D., McIntosh, T.C.,	and Walsh, R.A. (1998) J Clin Invest
		Tan, S., Hall, I.P., Dewar, J., Dow, E., and Lipwor	th, B. (1997) Lancet 350, 995-999.	
		Green, S.A., Cole, G., Jacinto, M., Innis, M., and L	iggett, S.B. (1993) J Biol Chem 268,	23116-23121.
		Shenker, A., Laue, L., Kosugi, S., Merendino, J.J.,	Minegishi, T., and Cutler, G.B. (199	3) Nature Lond 365, 652-654.
	٦	i n		•
	$\mathfrak{I}_{\mathbf{J}}$	"Introduction to 2- adrenocepta	rs "	nm Nm
		http://www.adrenoceptor.com/alphaintro.htm (V		/ n 1 1/2 \ / = 1/2 \ 1 1/2 \ \ = 1/4 \
				CPP. NIA) (author NIA)
		Robinson, E. and Hudson, A. "Adr http://www.tocris.com/adrenoceptor.htm, (visi	conscorter Dhamand	" m
		Kabinson, C. and Huasuri, T.	troceplor inarrivaca	ogy pris
Ω	J	http://www.tocris.com/adrenoceptor.ntm	ted March 12, 2001)	PP. NIA)
100 1	Ì	Voven	nber 1998	
		<u> </u>		
		ı		
	1			
,				
.				
		_		
EXAMINER —			DATE CONCIDEDED	
SAMITHVER	۲) ر	ara 18	DATE CONSIDERED 350	ን
			1-1	
EXAMINER: In	itial if ci	itation considered, whether or not citation is in conformat	nce with MPEP Section 609; Draw line ti	hrough citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.